Portola Pharma (PTLA) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:PTLA

18.03
+0.04 (+0.22%)
At close: Jul 1, 2020
18.02
-0.01 (-0.06%)
After Hours: 7/1/2020, 8:13:07 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

PTLA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.42B
Revenue(TTM)120.86M
Net Income(TTM)-281.28M
Shares78.48M
Float44.71M
52 Week High31.73
52 Week Low5.31
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-3.72
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
PTLA short term performance overview.The bars show the price performance of PTLA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

PTLA long term performance overview.The bars show the price performance of PTLA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of PTLA is 18.03 null. In the past month the price increased by 0.56%. In the past year, price decreased by -31.65%.

Portola Pharma / PTLA Daily stock chart

PTLA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to PTLA. When comparing the yearly performance of all stocks, PTLA is one of the better performing stocks in the market, outperforming 94.88% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
PTLA Full Technical Analysis Report

PTLA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to PTLA. Both the profitability and financial health of PTLA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
PTLA Full Fundamental Analysis Report

PTLA Financial Highlights

Over the last trailing twelve months PTLA reported a non-GAAP Earnings per Share(EPS) of -3.72. The EPS increased by 21.68% compared to the year before.


Industry RankSector Rank
PM (TTM) -232.73%
ROA -54.8%
ROE N/A
Debt/Equity 4.77
Chartmill High Growth Momentum
EPS Q2Q%13.73%
Sales Q2Q%19.04%
EPS 1Y (TTM)21.68%
Revenue 1Y (TTM)117.16%
PTLA financials

PTLA Forecast & Estimates


Analysts
Analysts88
Price TargetN/A
EPS Next Y39.41%
Revenue Next YearN/A
PTLA Analyst EstimatesPTLA Analyst Ratings

PTLA Ownership

Ownership
Inst Owners98.68%
Ins Owners5.95%
Short Float %N/A
Short RatioN/A
PTLA Ownership

About PTLA

Company Profile

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.

Company Info

Portola Pharma

270 EAST GRAND AVENUE

SOUTH SAN FRANCISCO CA 94080

CEO: Scott Garland

Phone: 650-246-7000

Portola Pharma / PTLA FAQ

What does PTLA do?

Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California.


What is the current price of PTLA stock?

The current stock price of PTLA is 18.03 null. The price increased by 0.22% in the last trading session.


What is the dividend status of Portola Pharma?

PTLA does not pay a dividend.


What is the ChartMill technical and fundamental rating of PTLA stock?

PTLA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the market capitalization of PTLA stock?

Portola Pharma (PTLA) has a market capitalization of 1.42B null. This makes PTLA a Small Cap stock.